- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07945977
Dosimetry of Organs at Risk for Lutathera Treatment Between Meningioma and Neuroendocrine Tumor (LUDOMET)
To Compare the Dosimetry of Organs at Risk in Patients Treated With Lutathera® for Meningioma Versus Neuroendocrine Tumor (NET).
Tumor dosimetry for meningiomas is substantially lower (7 to 8 times lower) than for neuroendocrine tumors (NETs), even though the injected activities are identical for both indications.
The hypothesis of this study is that organs at risk receive a higher absorbed dose in the case of meningiomas than with NETs.
A literature review has supported this hypothesis; therefore, it is appropriate to verify it through this retrospective study.
Study Overview
Status
Conditions
Detailed Description
Tumor dosimetry for meningiomas is substantially lower (7 to 8 times lower) than for neuroendocrine tumors (NETs), even though the injected activities are identical for both indications.
The hypothesis of this study is that organs at risk receive a higher absorbed dose in the case of meningiomas than with NETs.
A literature review has supported this hypothesis; therefore, it is appropriate to verify it through this retrospective study.Thus, the aim of the study will be to determine the dosimetry of organs at risk in patients treated with Lutathera® for meningioma and for a neuroendocrine tumor (NET).
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Antoine VERGER, MD,PhD
- Phone Number: +33 0383155567
- Email: a.verger@chru-nancy.fr
Study Contact Backup
- Name: Véronique Roch, MSc
- Phone Number: 0383154276
- Email: v.roch@chru-nancy.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
SPECT scans recorded for each patient who received at least one cycle of Lutathera® treatment for a meningioma or a NET will be analyzed.
Description
Inclusion Criteria:
- Patients who have received at least one course of Lutathera® treatment for a meningioma or a NET
Exclusion Criteria:
- Patient who has objected to the collection of their data
Study Plan
How is the study designed?
Design Details
- Observational Models: OTHER
- Time Perspectives: RETROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To compare the dosimetry of organs at risk in patients treated with Lutathera® for meningioma versus neuroendocrine tumor
Time Frame: Day 1
|
Calculation of dosimetry for organs at risk (kidney, spleen, liver, bone marrow) in the two patient populations treated with Lutathera® |
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To evaluate the safety monitoring of Lutathera® treatment in both populations at 3 months after the last Lutathera® cycle
Time Frame: 3 months
|
Biology results |
3 months
|
|
To evaluate the safety monitoring of Lutathera® treatment in both populations at 3 12 months after the last Lutathera® cycle
Time Frame: 12 months
|
Biology results |
12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2026PI163
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.